Toxicity and efficacy of Folfiri regimen and aflibercept combination in metastatic colorectal cancer: first results of a Russian multicenter retrospective study
Автор: Fedyanin M.Yu., Vladimirova L.Yu., Chubenko V.A., Zagorskaya L.A., Belyayeva A.V., Bolotina L.V., Moiseyenko F.V., Fakhrutdinova O.L., Belukhin S.A., Zhabina A.S., Khalikova L.V., Moiseyenko V.M., Meshcheryakov A.A., Artamonova E.V., Pokatayev I.A., Khasanova A.I., Belonogov A.V., Musayeva Kh.S., Novikova O.Yu., Stradayeva I. Yu., Popova I.L., Mukhametshina G.Z., Orlova R.V., Erdniev S.P., Ivanova A.K., Androsova A.V., Feoktistova P.S., Kuzmina Ye.S., Karabina Ye.V., Nekrasova O.V., Sherstnev V.M., Mishchenko A.A., Mukova L.A., Kertiev B.Kh., Kosar G.I., Osodoyeva S.N., Katz A.I., Malina R.R., Tryakin A.A., Tyulyandin S.A.
Журнал: Злокачественные опухоли @malignanttumors
Рубрика: Собственные исследования
Статья в выпуске: 2 т.9, 2019 года.
Бесплатный доступ
Purpose. To assess the incidence and severity of adverse events; to explore clinical factors associated with grade 3-4 non-hematologic toxicity; to assess the immediate efficacy and progression-free survival during treatment with the FOLFIRI regimen in combination with aflibercept in Russia. Materials and Methods. A retrospective multicenter study has been conducted with data collected from 20 clinics in 15 regions of Russia. There was no statistical hypothesis. Progression-free survival was the main efficacy criterion. The statistical analysis was performed using IBM SPPS Statistics v. 20 software. Results. FOLFIRI and Aflibercept combination was administered to 264 patients. The mean number of treatment cycles was 6 (1 to 29). The toxicity of aflibercept was addressed by dose reduction and dosing delay in 10.1 % and 11.4 % of patients, respectively, and dose reductions and dosing delays in any of FOLIFRI components were reported in 20.1 % of participants. The objective response rate was 20...
Colorectal cancer, chemotherapy, aflibercept, population study
Короткий адрес: https://sciup.org/140243823
IDR: 140243823 | DOI: 10.18027/2224-5057-2019-9-2-53-63
